2023-12-12 07:41:19 ET
DENVER, Colo., Dec 12, 2023 ( www.247marketnews.com )- C4 Therapeutics, Inc. (NASDAQ: CCCC) stated, this morning, that it entered into an exclusive license and collaboration agreement with Merck to develop degrader-antibody conjugates (DACs), an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells.
C4T is trading at $1.54, up $0.36 (+30.51%), on 3.8M shares traded.
Its 52-week range is $1.06 to $9.41. This hit a new 52-week low last week and may be driven higher by short covering.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an …
The post License and Research Collaboration with Merck has this Small Cap on Fire appeared first on 24/7 Market News .
For further details see:
License and Research Collaboration with Merck has this Small Cap on Fire